Tiziana Life Sciences (TLSA) Receivables - Other (2017 - 2025)

Tiziana Life Sciences has reported Receivables - Other for 9 years, with the latest figure at $558000.0 in Q4 2025.

• On a quarterly basis, Receivables - Other rose 215.25% year-over-year to $558000.0 in Q4 2025; TTM through Dec 2025 was $558000.0, a 215.25% increase from a year earlier, with the FY2025 full-year figure at $4.0 million, up 10.45% from the prior year.
• Receivables - Other was $558000.0 for Q4 2025 at Tiziana Life Sciences, down from $4.9 million in the prior quarter.
• The five-year high for Receivables - Other was $4.9 million in Q2 2025, with the low at -$1.5 million in Q4 2023.
• Average Receivables - Other over 5 years is $1.0 million, with a median of $511500.0 recorded in 2021.
• The sharpest annual moves came in 2022 and 2023: Receivables - Other plunged 1215.91% in 2022, then soared 499.84% in 2023.
• Over 5 years, Receivables - Other stood at -$88000.0 in 2021, then slumped by 1215.91% to -$1.2 million in 2022, then tumbled by 31.61% to -$1.5 million in 2023, then surged by 111.61% to $177000.0 in 2024, then soared by 215.25% to $558000.0 in 2025.
• The last three Receivables - Other figures came in at $558000.0 (Q4 2025), $4.9 million (Q2 2025), and $177000.0 (Q4 2024), per Business Quant data.